natgillin/translations-raw huggingface dataset:
Methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) Levetiracetam Actavis Group 100 mg/ml oral solution contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed). 
Metilparahidroksibenzoat (E218) i propilparahidroksibenzoat (E216) Levetiracetam Actavis Group 100 mg/ml oralna otopina sadrži metilparahidroksibenzoat (E218) i propilparahidroksibenzoat (E216) koji mogu izazvati alergijske reakcije (koje mogu biti i odgođene).
In paediatric patients (1 month to less than 4 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 116 patients and had a treatment duration of 5 days. 
U pedijatrijskih bolesnika (1 mjesec do manje od 4 godine života) djelotvornost levetiracetama dokazana je dvostruko slijepim i placebom kontroliranim ispitivanjem u 116 bolesnika koji su lijek dobivali 5 dana.
Levetiracetam efficacy was established in a double-blind, placebo-controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes. 
Djelotvornost levetiracetama dokazana je u dvostruko slijepom i placebom kontroliranom 16-tjednom ispitivanju u koje su bili uključeni bolesnici od 12 godina života i stariji s idiopatskom generaliziranom epilepsijom s miokloničkim napadajima kod različitih sindroma.
Wash the syringe with water after use and close the bottle with the plastic screw cap (Figure 10). 
Nakon uporabe štrcaljku isperite s vodom a bocu zatvorite plastičnim zatvaračem s navojem (slika 10).
Levetiracetam is not extensively metabolised in humans. 
Levetiracetam se kod ljudi ne metabolizira značajno.
Management of overdose 
Postupak kod predoziranja
Should your doctor decide to stop your Levetiracetam Actavis Group treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Actavis Group. 
Ako prekidate liječenje lijekom Levetiracetam Actavis Group, , prekid mora biti postupan kako bi se izbjeglo pojačanje napadaja.Ako Vaš liječnik odluči prekinuti liječenje lijekom Levetiracetam Actavis Group, uputit će Vas kako postupno prekinuti liječenje lijekom Levetiracetam Actavis Group.
As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam. 
Kako ni u odraslih, tako ni u pedijatrijskih bolesnika koji su dobivali do 60 mg/kg/dan levetiracetama nema dokaza o klinički značajnim interakcijama s lijekovima.
Adjustment of the dose is recommended in elderly patients with compromised renal function (see “Renal impairment” below). 
U starijih bolesnika sa smanjenom bubrežnom funkcijom preporučuje se prilagođavanje doze (vidjeti “Oštećenje bubrega” ispod).
Wash the syringe with water after use and close the bottle with the plastic screw cap (Figure 4). 
Nakon uporabe štrcaljku isperite s vodom a bocu zatvorite plastičnim zatvaračem s navojem (slika 4).
However, data suggested a 20 % higher levetiracetam clearance in children taking enzymeinducing antiepileptic medicinal products. 
Međutim, podaci su pokazali da antiepileptici koji induciraju enzimsku aktivnost kod djece povisuju klirens levetiracetama za 20%.
• suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, 
• pokušaj samoubojstva i suicidalne misli, mentalni poremećaj, poremećaj ponašanja,
Dosing adjustment for infants, children and adolescent patients weighing less than 50 kg with impaired renal function: 
Prilagođavanje doze kod dojenčadi, djece i adolescenata s manje od 50 kg tjelesne težine s oštećenom bubrežnom funkcijom Skupina
The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established. 
Kod monoterapije u djece i adolescenata mlađih od 16 godina sigurnost i djelotvornost levetiracetama nije dokazana.
28 mg (0.3 ml) twice daily 84 mg (0.85 ml) twice daily 
28 mg (0,3 ml) dva puta na dan 84 mg (0,85 ml) dva puta na dan
Rare: may affect up to 1 in 1,000 people 
Rijetko: mogu se javiti u manje od 1 na 1000 osoba
Levetiracetam has been given to you by your doctor to reduce the number of fits. 
Vaš liječnik Vam je propisao levetiracetam kako bi se smanjio broj napadaja.
35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged < 6 months. 
U placebom kontroliranim kliničkim ispitivanjima lijeku je bilo izloženo 35 dojenčadi mlađe od 1 godine s parcijalnim napadajima, a samo je njih 13 bilo u dobi ˂ 6 mjeseci.
General dose: Levetiracetam Actavis Group is taken twice daily, in two equally divided doses, each individual dose being measured between 5 ml (500 mg) and 15 ml (1,500 mg). 
Uobičajena doza: Levetiracetam Actavis Group se uzima dva puta na dan, u dvije jednake doze, pri čemu svaka pojedinačna doza iznosi između 5 ml (500 mg) i 15 ml (1500 mg).
Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1,800 mg/kg/day (x 6- 17 the MRHD on a mg/m2 basis). 
Neonatalna i juvenilna ispitivanja na štakorima i psima pokazala su da nema nuspojava u uobičajenim mjerama ishoda razvoja ili sazrijevanja kod primjene doza do 1800 mg/kg/dan (6-erostruka do 17erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
General dose: Levetiracetam Actavis Group is taken twice daily, in two equally divided doses, each individual dose being measured between 0.07 ml (7 mg) and 0.21 ml (21 mg), per kg bodyweight of the infant. 
Uobičajena doza: Levetiracetam Actavis Group se uzima dva puta na dan, u dvije jednake doze, pri čemu svaka pojedinačna doza iznosi između 0,07 ml (7 mg) i 0,21 ml (21 mg) po kilogramu tjelesne težine dojenčeta.
In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores. 
Studije in vitro pokazuju da levetiracetam utječe na razinu Ca2+ u neuronima na način da djelomično inhibira
• signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements. 
izrazitu pospanost, amneziju (gubitak pamćenja), slabljenje pamćenja (zaboravljivost), abnormalno ponašanje ili druge neurološke znakove uključujući nevoljne ili nekontrolirane pokrete.
Levetiracetam Actavis Group treatment for as long as your doctor has told you. 
Trebate nastaviti liječenje lijekom Levetiracetam Actavis Group onoliko dugo koliko je liječnik odredio.
Dose recommendations for infants aged from 1 month to less than 6 months: 
Preporučene doze za dojenčad u dobi od 1 mjeseca do manje od 6 mjeseci:
As with all antiepileptic medicines, sudden discontinuation of levetiracetam should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. Monotherapy should be preferred whenever possible because therapy with multiple antiepileptic medicines AEDs could be associated with a higher risk of congenital malformations than monotherapy, depending on the associated antiepileptics. 
Poželjna je monoterapija kad god je to moguće jer bi terapija kombinacijama antiepileptika mogla biti povezana s većim rizikom od kongenitalnih malformacija u odnosu na monoterapiju, ovisno o dotičnim antiepilepticima.
Antiepileptic medicinal products 
Antiepileptici
In both population pharmacokinetic analyses, there was about a 20% increase of apparent clearance of levetiracetam when it was co-administered with an enzyme-inducing antiepileptic medicinal product. 
U obje farmakokinetičke analize populacije prividni klirens levetiracetama se povećao za oko 20 %
Levetiracetam Actavis Group oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. 
(1) Za doze ispod 250 mg, za doze koje nisu višekratnici od 250 mg, odnosno kada preporučeno doziranje ne može biti postignuto uzimanjem većeg broja tableta i kod bolesnika koji ne mogu gutati tablete treba koristiti Levetiracetam Actavis Group oralnu otopinu.
• skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens 
• osip kože koji se može formirati u mjehuriće i izgledati kao male mete (sa središnjim tamnim točkama okruženim bljeđim područjem i tamnim prstenom oko ruba) (erythema multiforme), jako rasprostranjen osip s mjehurićima i kožom koja se ljušti, osobito oko usta, nosa, očiju i genitalija (Stevens-Johnsonov sindrom), i mnogo teži oblik koji uzrokuje ljuštenje kože na više od 30% površine tijela (toksična epidermalna nekroliza);
49 mg (0.5 ml) twice daily 147 mg (1.5 ml) twice daily 
49 mg (0,5 ml) dva puta na dan 147 mg (1,5 ml) dva puta na dan
With continued long-term treatment, 47.4% of the patients were free of tonic-clonic seizures for at least 6 months and 31.5% were free of tonic-clonic seizures for at least 1 year. 
S nastavkom dugotrajnog liječenja 47,4 % bolesnika bilo je barem 6 mjeseci i 31,5 % barem 1 godinu bez toničko-kloničkih napadaja.
Maltitol liquid (E965) Acesulfame potassium (E950) Grape flavour (contains propylene glycol) Purified water 
acesulfamkalij (E950) aroma grožđa (sadrži propilenglikol)
The 300 ml glass bottle of Levetiracetam Actavis Group (for children aged 4 years and above, adolescents and adults) is packed in a cardboard box containing a 10 ml oral syringe (graduated every 0.25 ml). 
Staklena boca od 300 ml lijeka Levetiracetam Actavis Group (za djecu u dobi od 4 godine i stariju, adolescente i odrasle) pakirana je u kartonsku kutiju koja još sadrži štrcaljku za usta od 10 ml (s oznakom na svakih 0,25 ml).
The NOAEL was ≥ 1,800 mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning (x 6 the MRHD on a mg/m2 basis). 
NOAEL je iznosila ≥ 1800 mg/kg/dan za F0 ženke te za preživljenje, rast i razvoj za F1 potomstvo do odbića (6-erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
Add-on therapy for infants from 1 month to less than 6 months 
Dodatna terapija za dojenčad u dobi od 1 mjeseca do manje od 6 mjeseci
The initial therapeutic dose is 500 mg twice daily. 
Početna terapijska doza iznosi 500 mg dva puta na dan.
35 mg (0.35 ml) twice daily 105 mg (1.05 ml) twice daily 
35 mg (0,35 ml) dva puta na dan 105 mg (1,05 ml) dva puta na dan
Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks. 
Doza se može povećavati ili smanjivati za po 500 mg dva puta na dan svaka dva do četiri tjedna.
Liver function test abnormal 
Abnormalni nalazi jetrene funkcije
(1) A 750 mg loading dose is recommended on the first day of treatment with levetiracetam. 
(1) Prvog dana liječenja levetiracetamom preporučuje se udarna doza od 750 mg.
For children above 4 years, measure the appropriate dosage using the 10 ml syringe included in the package. 
Za djecu od navršene 4 godine nadalje odgovarajuću dozu izmjerite pomoću štrcaljke od 10 ml koja se nalazi u pakiranju.
Adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy. 
Dodatna terapija primarno generaliziranih toničko-kloničkih napadaja u odraslih i adolescenata starijih od 12 godina života s idiopatskom generaliziranom epilepsijom.
Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy: 
Dodatna terapija djelomičnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih, adolescenata, djece i dojenčadi od 1. mjeseca života nadalje koji pate od epilepsije.
Citric acid monohydrate Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Ammonium glycyrrhizate 
6.1 Popis pomoćnih tvari natrijev citrat citratna kiselina hidrat metilparahidroksibenzoat (E218) propilparahidroksibenzoat (E216) amonijev glicirizat glicerin glicerol (E422)
(5) Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended. 
(5) Nakon dijalize preporučuje se dodatna doza od 5 do 10 mg/kg (0,05 do 0,10 ml/kg).
Infants 6 to 23 months, children and adolescents weighing less than 50 kg 
mjeseca, djeca i adolescenti teški manje od 50 kg
Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. 
Monoterapija u liječenju djelomičnih napadaja sa sekundarnom generalizacijom ili bez nje u bolesnika od navršene 16. godine života s novodijagnosticiranom epilepsijom.
Levetiracetam is a highly soluble and permeable compound. 
Levetiracetam je lako topiva i permeabilna tvar.
In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1,000 mg, 2,000 mg, or 3,000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks. 
Djelotvornost levetiracetama dokazana je u odraslih u 3 dvostruko slijepa i placebom kontrolirana ispitivanja gdje su bolesnici tijekom liječenja 18 tjedana dobivali 1000 mg, 2000 mg ili 3000 mg/dan,
Three presentations are available: - A 300 ml bottle with a 10 ml oral syringe (delivering up to 1,000 mg levetiracetam) graduated every 0.25 ml (corresponding to 25 mg). 
Dostupne su tri veličine pakiranja: - Bočica od 300 ml s 10 ml štrcaljkom za usta (koja isporučuju do 1000 mg levetiracetama) s podjelama po 0,25 ml (što odgovara količini od 25 mg).
A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation). 
(omjer koncentracija u slini i plazmi je u rasponu od 1 do 1,7 za lijek u obliku oralne tablete te nakon 4 sata od uzimanja lijeka u obliku oralne otopine).
The initial therapeutic dose is 10 mg/kg twice daily. 
Početna terapijska doza iznosi 10 mg/kg dva puta na dan.
The NOAEL was <200 mg/kg/day for the dams and 200 mg/kg/day for the fetuses (equal to the MRHD on a mg/m2 basis). 
NOAEL je za gravidne ženke iznosila <200 mg/kg/dan, a za fetuse 200 mg/kg/dan (što je jednako MRHD-u, engl.
What you need to know before you take Levetiracetam Actavis Group Do not take Levetiracetam Actavis Group 
Što morate znati prije nego počnete uzimati Levetiracetam Actavis Group
BSA subject (m2) 
PT bolesnika (m2)
Pull the syringe by the dosing body out of the bottle (Figure 2). 
Uklonite štrcaljku iz boce držeći je za graduirano tijelo (slika 2).
Oral use. 
Oralna otopina.
The initial therapeutic dose is 7 mg/kg twice daily. 
Početna terapijska doza je 7 mg/kg dva puta na dan.
Starting dose: 0.1 ml/kg twice daily Maximum dose: 0.3 ml/kg twice daily 
Početna doza: 0,1 ml/kg dva puta na dan Najveća doza: 0,3 ml/kg dva puta na dan
Weight decreased , weight increase 
povećanje tjelesne težine
IJsland / Islande / Island Tél/Tel: +354 5503300 
Actavis Group PTC ehf. Islande / Island Tél/Tel: +354 5503300
With continued long-term treatment, 28.6% of the patients were free of myoclonic seizures for at least 6 months and 21.0% were free of myoclonic seizures for at least 1 year. 
S nastavkom dugotrajnog liječenja 28,6 % bolesnika bilo je barem 6 mjeseci i 21,0 % barem 1 godinu bez miokloničkih napadaja.
With continued long-term treatment, 11.4% of the patients were seizure-free for at least 6 months and 7.2% were seizure-free for at least 1 year. 
S nastavkom dugotrajnog liječenja 11,4% bolesnika bilo je barem 6 mjeseci, a 7,2 % barem 1 godinu bez napadaja.
• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. 
• u liječenju miokloničkih napadaja u odraslih i adolescenata od 12. godine života s juvenilnom miokloničnom epilepsijom.
For children 6 months to 4 years, measure the appropriate dosage using the 3 ml syringe included in the package. 
Za djecu od navršenih 6 mjeseci do manje od 4 godine, odgovarajuću dozu izmjerite pomoću štrcaljke od 3 ml koja se nalazi u pakiranju.
If you stop taking Levetiracetam Actavis Group 
Ako prestanete uzimati Levetiracetam Actavis Group
Levetiracetam Actavis Group 100 mg/ml oral solution contains maltitol liquid. 
Levetiracetam Actavis Group 100 mg/ml oralna otopina sadrži tekući maltitol.
If you forget to take Levetiracetam Actavis Group 
Ako ste zaboravili uzeti Levetiracetam Actavis Group
The administration of levetiracetam to patients with renal impairment may require dose adjustment. 
U bolesnika s oštećenjem bubrega može biti potrebno prilagođavanje doze levetiracetama
Turn the bottle upside down with the syringe still in place (Figure 4). 
Okrenite bocu naopako; štrcaljka treba i dalje biti pričvršćena (slika 4).
Starting dose: 0.07 ml/kg twice daily Maximum dose: 0.21 ml/kg twice daily 
Početna doza: 0,07 ml/kg dva puta na dan Najveća doza: 0,21 ml/kg dva puta na dan
The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness. 
Sažetak sigurnosnog profila Najčešće prijavljene nuspojave bile su nazofaringitis, somnolencija, glavobolja, umor i omaglica.
Results related to behavioral and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardised and systematic way using a validated instrument (CBCL - Achenbach Child Behaviour Checklist). 
Rezultati ocjene funkcioniranja ponašanja i emocionalnog funkcioniranja uputili su na pogoršanje u smislu agresivnijeg ponašanja u skupini koja je uzimala levetiracetam, ocijenjenog validiranim instrumentom
The 300 ml glass bottle of Levetiracetam Actavis Group (for infants aged 1 month to less than 6 months) is packed in a cardboard box containing a 1 ml oral syringe (graduated every 0.05 ml) and an adaptor for the syringe. 
Staklena boca od 300 ml lijeka Levetiracetam Actavis Group (za dojenčad u dobi od 1 mjeseca do manje od 6 mjeseci) pakirana je u kartonsku kutiju koja još sadrži štrcaljku za usta od 1 ml (s oznakom na svakih 0,05 ml) i nastavak za štrcaljku.
(4) Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended. 
Nakon dijalize preporučuje se dodatna doza od 3,5 do 7 mg/kg (0,035 do 0,07 ml/kg).
With continued long-term treatment, 8.6% of the patients were seizure-free for at least 6 months and 7.8 % were seizure-free for at least 1 year. 
Dugoročno je liječenje pokazalo da 8,6 % bolesnika nije imalo napadaje tijekom najmanje 6 mjeseci, a njih 7,8 % nije imalo napadaje tijekom najmanje 1 godine.
• convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), 
• konvulzije, poremećaj ravnoteže, omaglica (osjećaj nestabilnosti), bezvoljnost (nedostatak energije i elana), tremor (nevoljno drhtanje);
In the elderly, the half-life is increased by about 40% (10 to 11 hours). 
U starijih osoba poluvijek u plazmi povećano je za oko 40 % (10 do 11 sati), što je u svezi sa smanjenjem bubrežne funkcije unutar te populacije (vidjeti dio 4.2).
In this study, levetiracetam, dose was 3,000 mg/day given in 2 divided doses. 
Primijenjena doza kod ispitivanja bila je 3000 mg/dan podjeljeno na dvije doze.
Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. 
Dodatna terapija miokloničkih napadaja u odraslih i adolescenata starijih od 12 godina života s juvenilnom miokloničnom epilepsijom.
Hyponatraemia 
Hiponatremija
300 ml oral solution with a 10 ml oral syringe. 
300 ml oralne otopine sa štrcaljkom za usta od 10 ml.
- A 300 ml bottle with a 3 ml oral syringe (delivering up to 300 mg levetiracetam) graduated every 0.1 ml (corresponding to 10 mg). 
- Bočica od 300 ml s 3 ml štrcaljkom za usta (koja isporučuje do 300 mg levetiracetama) s podjelama po 0,1 ml (što odgovara količini od 10 mg).
No adverse reactions on male or female fertility or reproduction performance were observed in rats at doses up to 1,800 mg/kg/day (x 6 the MRHD on a mg/m2 or exposure basis) in parents and F1 generation. 
Kod mužjaka i ženki štakora roditeljske i F1 generacije nisu primijećeni nuspojave na plodnost ili na reprodukciju u dozama do 1800 mg/kg/dan (6-erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2 ili na osnovnu izloženost).
Diplopia, vision blurred 
Diplopija, zamagljen vid
• abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea; 
• bol u trbuhu, proljev, dispepsija (loša probava), povraćanje, mučnina;
- A 300 ml bottle with a 1 ml oral syringe (delivering up to 100 mg levetiracetam) graduated every 0.05 ml (corresponding to 5 mg). 
- Bočica od 300 ml s 1 ml štrcaljkom za usta (koja isporučuje do 100 mg levetiracetama) s podjelama po 0,05 ml (što odgovara količini od 5 mg).
confusion, panic attack, emotional instability/mood swings, agitation; 
halucinacije, srditost, smetenost, napadaj panike, emocionalna nestabilnost/promjene raspoloženja, uznemirenost;
The NOAEL (No Observed Adverse Effect Level) was 3,600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m2 basis) and 1,200 mg/kg/day for fetuses. 
No Observed Adverse Effect Level, razina pri kojoj se ne uočava štetni učinak) za gravidne štakorice iznosila je 3600 mg/kg/dan, a za fetuse 1200 mg/kg/dan (12-erostruka vrijednost najveće preporučene doze za čovjeka izražena u mg/m2).
(3) A 15 mg/kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam. 
(3) Prvog dana liječenja levetiracetamom preporučuje se udarna doza od 15 mg/kg (0,15 ml/kg).
CLcr (ml/min/1.73 m2) = -----------------------------------Serum Creatinine (mg/dl) 
visina (cm) x ks CLcr (ml/min/1,73 m2) = -----------------------------------kreatinin u serumu (mg/dl)
Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses. 
Kod predoziranja levetiracetamom primijećena je somnolencija, agitacija, agresivnost, smanjena razina svijesti, depresija disanja i koma.
In addition, the oral solution should be used for initial treatment in children weighing less than 25 kg, 
Osim toga, oralnu otopinu treba upotrijebiti za početak liječenja u djece lakše od 25 kg, u bolesnika koji ne mogu gutati tablete ili za davanje doza manjih od 250 mg.
General dose: Levetiracetam Actavis Group is taken twice daily, in two equally divided doses, each individual dose being measured between 0.1 ml (10 mg) and 0.3 ml (30 mg), per kg bodyweight of the child. (see table below for dose examples). 
Uobičajena doza: Levetiracetam Actavis Group se uzima dva puta na dan, u dvije jednake doze, pri čemu svaka pojedinačna doza iznosi između 0,1 ml (10 mg) i 0,3 ml (30 mg) po kilogramu tjelesne težine djeteta.
How to take Levetiracetam Actavis Group 
Kako uzimati Levetiracetam Actavis Group
Levetiracetam Actavis Group 100 mg/ml oral solution Levetiracetam 
Levetiracetam Actavis Group 100 mg/ml oralna otopina levetiracetam
in adults and adolescents from 12 years of age with idiopathic generalised epilepsy 
godine života s idiopatskom generaliziranom epilepsijom.
• amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia 
• amnezija (gubitak pamćenja), smetnje pamćenja (zaboravljivost), poremećaj koordinacije/ataksija (poremećaj koordinacije pokreta), parestezije (trnci), smetnje u koncentraciji (gubitak koncentracije);
Levetiracetam Actavis Group 100 mg/ml oral solution is a clear, faint yellowish-brown solution. 
Levetiracetam Actavis Group 100 mg/ml oralna otopina je bistra, blijedo žućkasto-smeđa otopina.
220 Hafnarfjörður Iceland 
Actavis Group PTC ehf. 220 Hafnarfjörður Island